From Trial to Practice: Real-World Outcomes and The Evolving SERD Landscape

EP: 1.When Stable Disease Progresses: ESR1 Mutations at the Point Of Progression In Juliana’s Case

EP: 2.Targeting Resistance: Liquid Biopsy and the Role of SERDs In ESR1-Mutated mBC

EP: 3.Oral SERDs In Focus: EMERALD Findings and Practical Considerations for Evidence-Based Treatment Selection

EP: 4.Safety Profile and Patient Guidance for Elacestrant: Practical Considerations With Oral Elacestrant

Now Viewing

EP: 5.From Trial to Practice: Real-World Outcomes and The Evolving SERD Landscape

EP: 6.Optimizing Multidisciplinary Care for ESR1-Mutated Breast Cancer: Strategies and Future Directions

Video content above is prompted by the following:

The conversation shifts to real-world data and experiences with elacestrant, presenting insights from the San Antonio Breast Cancer Symposium. Rikal shares findings from the Komodo Health research database, which demonstrated promising real-world progression-free survival outcomes. The real-world data showed a time-to-next treatment of 6.43 months and a progression-free survival of 6.8 months overall, with even more impressive results of 9.4 months for patients without prior fulvestrant exposure.

The panelists discuss the excitement surrounding combination therapy trials for elacestrant, highlighting several ongoing studies exploring its potential in various combinations. These include trials combining elacestrant with antiandrogens, CDK 4/6 inhibitors, and other targeted therapies. Marti-Smith expresses optimism about these combination approaches, believing that targeting different areas might provide more comprehensive cancer treatment and potentially improve patient outcomes.

The discussion also explores innovative trial designs, such as monitoring for estrogen receptor 1 (ESR1) mutation emergence and proactively switching therapies. Traina mentions trials such as EMBER 3 and SERENA that aim to track circulating tumor DNA for ESR1 mutations and implement strategic therapy switches. These approaches represent a forward-thinking method of personalized medicine, potentially allowing patients to remain on effective treatments for longer periods by addressing resistance mechanisms as they develop.